Appointments

STORM Therapeutics is a biotechnology company specialising in discovering and developing novel small molecule therapies targeting RNA modification enzymes for oncology and other diseases. Dr McMahon has more than 30 years’ experience in biotechnology leadership, scientific innovation, creative deal-making, and financing experience with expertise in a broad range of diseases, and a specialty in oncology therapeutics.

Dr Jerry McMahon stated, “STORM is well positioned to fulfil its ambition of becoming the global leader in the field of RME. STORM’s firstin-class clinical candidate STC-15, an orallybioavailable, highly selective METTL3 inhibitor, is on schedule to start initial clinical studies in solid tumours in 2022, and will be the first-ever RME inhibitor molecule to enter clinical development. I look forward to guiding STORM through future growth, capitalising on our world leading RME drug discovery experience, advancing programs into the clinic, and building the pipeline which was recently validated with a significant partner in oncology.”